The Drug Revolving Fund is a self-sustaining financing mechanism designed to guarantee continuous availability of essential medicines in healthcare facilities. Seed capital buys an initial stock of drugs. As patients purchase these medications, the revenue generated returns to the fund, creating a pool of money solely dedicated to purchasing replacement stock. This cyclical process prevents stockouts caused by bureaucratic delays in government budget releases. Maintaining the capital base requires strict pricing and revenue discipline. If cash leaks out of the system or drugs are given out on credit without recovery, the fund collapses, and the pharmacy runs dry.
Financial control in a Drug Revolving Fund protects capital integrity against depletion, theft, and waste. Every naira must be accounted for from the point of sale to the bank deposit. Core principles include segregation of duties, where the person selling the drug is never the same person reconciling the bank account. Transparency ensures that stakeholders can trace transactions without stress. Regular financial monitoring catches discrepancies early before minor shortages become massive deficits that cripple procurement.
Daily cash collections form the lifeblood of the revolving fund. Pharmacies must enforce prompt banking habits, ensuring cash does not sit overnight in unsecured drawers.
Setting the right price determines whether the fund grows or dies. Prices must cover the basic procurement cost, shipping, storage losses, and a small inflation buffer to ensure future purchasing power. Underpricing guarantees capital erosion because the revenue from selling a drug will not buy the same quantity next time. Overpricing defeats the public health goal by making essential medicines unaffordable for vulnerable patients.
Inventory represents tied-up capital. Poor stock management leads to dead stock, expiration, and theft, which directly drains financial resources.
| Valuation Method | Description | Financial Implication |
|---|---|---|
| FIFO | First-In, First-Out | Sells older stock first, preventing expiry loss |
| Weighted Average | Blends costs of old and new stock | Smooths out price fluctuations |
Pharmacy staff must conduct periodic physical stock counts to reconcile physical items with stock ledger balances.
Procurement is where the largest chunks of fund capital leave the facility. Open, competitive bidding prevents collusion and ensures the facility gets quality drugs at the best market rates. Transparency requires multiple price quotations from accredited manufacturers or distributors before placing orders. Inflated purchase invoices or single-source buying without justification creates avenues for corruption and drains the revolving fund.
Accurate accounting provides the evidence trail needed for financial accountability. Stock cards, cash books, receipt booklets, and ledger accounts must be updated daily. Internal and external audits review these documents to catch errors, discrepancies, or fraudulent activities. Regular auditing reassures management and funding bodies that the revolving fund operates with integrity and remains capable of sustaining drug supplies.
Drug Revolving Funds face recurring pressures that threaten sustainability. Credit sales to influential personnel or patients often turn into bad debts that never return. Inflation devalues cash reserves faster than prices can be adjusted. Mitigation strategies include enforcing a strict cash-and-carry policy with zero tolerance for credit, automating inventory systems to minimize human error, and reviewing pricing structures periodically to match prevailing market realities.